Umecrine AB is active in research and development of pharmaceutical agents against negative mental and neurological symptoms caused by natural CNS-active stress- and sex steroids (GABA-steroids). There are several different indications on Umecrine's current work list, conditions related to e.g. anxiety and mood, memory, depression, alcohol abuse and regulation of appetite. Umecrine's portfolio includes a number of newly discovered lead compounds and several drug candidates that are under investigation.
The company was founded in 2000 by leading scientists in the area of GABA-steroids at the University of Umeå, Sweden. The company has two subsidiaries
|
Torbjörn Bäckström, MD, PhD CEO torbjorn.backstrom@umecrine.se phone +46 72 203 1313 |
Address: Umeå Neurosteroid Research Center, Norrlands University Hospital, By 5B 5tr SE-901 85 Umeå, Sweden |
